Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kendra Louise Nelson is active.

Publication


Featured researches published by Kendra Louise Nelson.


Journal of Medicinal Chemistry | 2010

Design of selective, ATP-competitive inhibitors of Akt.

Kevin Daniel Freeman-Cook; Christopher Autry; Gary Borzillo; Deborah Gordon; Elsa G. Barbacci-Tobin; Vincent Bernardo; David Briere; Tracey Clark; Matthew Corbett; John Jakubczak; Shefali Kakar; Elizabeth Knauth; Blaise Lippa; Michael Joseph Luzzio; Mahmoud N. Mansour; Gary J. Martinelli; Matthew A. Marx; Kendra Louise Nelson; Jayvardhan Pandit; Francis Rajamohan; Shaughnessy Robinson; Chakrapani Subramanyam; Liuqing Wei; Martin James Wythes; Joel Morris

This paper describes the design and synthesis of novel, ATP-competitive Akt inhibitors from an elaborated 3-aminopyrrolidine scaffold. Key findings include the discovery of an initial lead that was modestly selective and medicinal chemistry optimization of that lead to provide more selective analogues. Analysis of the data suggested that highly lipophilic analogues would likely suffer from poor overall properties. Central to the discussion is the concept of optimization of lipophilic efficiency and the ability to balance overall druglike propeties with the careful control of lipophilicity in the lead series. Discovery of the nonracemic amide series and subsequent modification produced an advanced analogue that performed well in advanced preclinical assays, including xenograft tumor growth inhibition studies, and this analogue was nominated for clinical development.


Journal of Medicinal Chemistry | 2012

Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase.

Kevin Daniel Freeman-Cook; Paul Amor; Scott Bader; Leanne M. Buzon; Steven B. Coffey; Jeffrey W. Corbett; Kenneth J. DiRico; Shawn D. Doran; Richard L. Elliott; William Esler; Angel Guzman-Perez; Kevin E. Henegar; Janet A. Houser; Christopher S. Jones; Chris Limberakis; Katherine Loomis; Kirk McPherson; Sharad Murdande; Kendra Louise Nelson; Dennis Paul Phillion; Betsy S. Pierce; Wei Song; Eliot Sugarman; Susan Tapley; Meihua Tu; Zhengrong Zhao

This paper describes the design and synthesis of a novel series of dual inhibitors of acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2). Key findings include the discovery of an initial lead that was modestly potent and subsequent medicinal chemistry optimization with a focus on lipophilic efficiency (LipE) to balance overall druglike properties. Free-Wilson methodology provided a clear breakdown of the contributions of specific structural elements to the overall LipE, a rationale for prioritization of virtual compounds for synthesis, and a highly successful prediction of the LipE of the resulting analogues. Further preclinical assays, including in vivo malonyl-CoA reduction in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analogue that progressed to regulatory toxicity studies.


Synthetic Communications | 2012

Synthesis of Unprotected Carboxy Indazoles via Pd-Catalyzed Carbonylation

Philip Wainwright; Remedios Perni; Clare Vickers; Steven B. Coffey; Leanne M. Buzon; Kenneth J. DiRico; Kendra Louise Nelson; Zhengrong Zhao; Chris Limberakis; Kevin Daniel Freeman-Cook; Jeffrey W. Corbett

Abstract The first published synthesis of unprotected carboxy indazoles from the corresponding bromoindazoles is described. This is achieved via Pd(II)-catalyzed carbonylation and is demonstrated to work on a variety of indazoles. GRAPHICAL ABSTRACT


Archive | 2008

Sulfonyl amide derivatives for the treatment of abnormal cell growth

Michael Joseph Luzzio; Kevin Daniel Freeman-Cook; Samit Kumar Bhattacharya; Matthew Merrill Hayward; Catherine A. Hulford; Christopher Autry; Xumiao Zhao; Jun Xiao; Kendra Louise Nelson


Bioorganic & Medicinal Chemistry Letters | 2006

Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.

Kim F. McClure; Michael A. Letavic; Amit S. Kalgutkar; Christopher A. Gabel; Laurent P. Audoly; John T. Barberia; John Frederick Braganza; Demetrius Carter; Thomas J. Carty; Santo R. Cortina; Mark A. Dombroski; Kathleen M. Donahue; Nancy C. Elliott; Colleen P. Gibbons; Crystal K. Jordan; Alexander V. Kuperman; Jeff M. Labasi; Ronald E. Laliberte; Jennifer M. McCoy; Brian M. Naiman; Kendra Louise Nelson; Hang T. Nguyen; Kevin M. Peese; Francis J. Sweeney; Timothy J. Taylor; Catherine E. Trebino; Yuriy A. Abramov; Ellen R. Laird; Walter Volberg; Jun Zhou


Cancer Research | 2008

SAR and chemistry of Aurora kinase inhibitors: Discovery of PF-3814735, an oral clinical candidate

Samit Kumar Bhattacharya; Donn G. Wishka; Michael Joseph Luzzio; Vincent Bernardo; David Briere; Tracy Lee Boyden; Mary Campbell; Bruce M. Cohen; Kevin Coleman; Erling Emerson; John Jakubczak; Jitesh P. Jani; Chao Li; Matthew A. Marx; James D. Moyer; Kendra Louise Nelson; Gonghua Pan; Leslie R. Pustilnik; Kristina Rafidi; Ann Marie Rossi; Rick Shepard; Stefanus J. Steyn; Chunyan Su; Shusen Sun; Kostantinos Tsaparikos; Courtney Williams; Jun Xiao; Kwansik Yoon; Xumiao Zhao


Archive | 2010

DERIVADOS DE PIRIDINA PARA EL TRATAMIENTO DEL CRECIMIENTO CELULAR ANORMAL

Samit Kumar Bhattacharya; Arthur D. Brosius; Michael Joseph Luzzio; Kendra Louise Nelson; Gonghua Pan; James A. Southers; Donn G. Wishka; Jun Xiao


Journal of Medicinal Chemistry | 2010

Corrections to Design of Selective, ATP-Competitive Inhibitors of Akt

Kevin Daniel Freeman-Cook; Christopher Autry; Gary Borzillo; Deborah Gordon; Elsa G. Barbacci-Tobin; Vincent Bernardo; David Briere; Tracey Clark; Matthew Corbett; John Jakubczak; Shefali Kakar; Elizabeth Knauth; Blaise Lippa; Michael Joseph Luzzio; Mahmoud N. Mansour; Gary J. Martinelli; Matthew A. Marx; Kendra Louise Nelson; Jayvardhan Pandit; Francis Rajamohan; Shaughnessy Robinson; Chakrapani Subramanyam; Liuqing Wei; Martin James Wythes; Joel Morris


Archive | 2008

Sulfonylamid-derivate zur behandlung von abnormalem zellwachstum

Michael Joseph Luzzio; Christopher Autry; Samit Kumar Bhattacharya; Kevin Daniel Freeman-Cook; Matthew Merrill Hayward; Catherine A. Hulford; Kendra Louise Nelson; Jun Xiao; Xumiao Zhao


Archive | 2008

Sulfonylamid-derivater til behandling af unormal cellevækst.

Michael Joseph Luzzio; Christopher Autry; Samit Kumar Bhattacharya; Kevin Daniel Freeman-Cook; Matthew Merrill Hayward; Catherine A. Hulford; Kendra Louise Nelson; Jun Xiao; Xumiao Zhao

Collaboration


Dive into the Kendra Louise Nelson's collaboration.

Researchain Logo
Decentralizing Knowledge